$P

Colgrove John sold $7.1M of P (indirect holdings)

Colgrove John (Chief Visionary Officer) sold 100,000 indirectly-held shares of Everpure, Inc. (P) at an average of $71.04 ($70.00–$71.54, $7.10M total) across 5 trades over 2026-06-10 to 2026-06-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Colgrove John
Published Jun 12, 2026, 8:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$P
Neutral
medium confidence
Mentioned
$P
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PNeutralLow
01

Why it matters

It documents an officer/director’s open-market sale of 100,000 shares (~$7.1M) executed over 2026-06-10 to 2026-06-12 under a pre-arranged Rule 10b5-1 plan.

02

Market read

Traders may monitor for sentiment/flow effects from insider selling, but the 10b5-1 structure generally limits interpretive weight.

03

What to watch

Check whether this sale is part of a larger, recurring 10b5-1 schedule and whether other insiders simultaneously sell/buy; single Form 4s can be noisy without that context.

Relevance 5/10Novelty 5/10Timing: Filed 2026-06-12 (covers sales 2026-06-10 to 2026-06-12).

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Everpure, Inc. (P).

Company-level read

Ticker impact

$PNeutralMedium confidence
Context

Everpure (P) reported an insider Form 4: Colgrove John sold ~$7.1M of shares (100,000) via an open-market sale under a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; watch for follow-on insider activity or unusual volume rather than expecting a sustained move from this filing alone.

Evidence & confidence

The filing is a Form 4 open-market sale by an officer/director with an explicitly pre-arranged 10b5-1 plan, which typically reduces signaling value versus discretionary selling.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, the market may overreact; price action could be driven more by broader tape/earnings than insider flow.

Key entities

  • Everpure, Inc.

    Company whose shares were sold by an insider; Form 4 filed on SEC EDGAR.

  • Colgrove John

    Chief Visionary Officer; reported open-market sale of 100,000 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHighAI 8/10

Everpure (P) Shares Rise After CFRA Upgrade and Strong Fiscal 20

Everpure Inc (NYSE: P) shares rose 3% after CFRA upgraded it from Sell to Buy, citing raised guidance for fiscal 2028. The company projects $7B-$7.3B in revenue and $1.7B-$1.9B in non-GAAP operating income, driven by demand for its all-flash storage solutions in AI data centers. Despite this, GuruFocus's GF Value™ suggests the stock is overvalued at $126.00, with an intrinsic value of $81.40.

$METAMedAI 8/10

Meta, Everpure, Akamai Technologies, Apimeds Pharmaceuticals and Costco: Why These 5 Stocks Are on Invest

Meta (META) rose 4.5% to $777.59, driven by AI strategy. Everpure (P) surged 11.15% to $121.88, reaffirming fiscal 2027 guidance. Akamai (AKAM) fell 6.78% to $110.41, then jumped 20.65% after-hours on a $11.6B AI deal. Apimeds (APUS) soared 114.85% to $4.92 on a blockchain agreement. Costco (COST) dipped 0.91% to $896.48 despite beating Q4 estimates.

$PHighAI 8/10

Everpure Stock Jumps As S&P 500 Inclusion Fuels Momentum

Everpure Inc. (NYSE: P) stock rose 12.77% after its inclusion in the S&P 500. The company's shares have climbed from the low-$90s to $121.88, with a high of $131.41. Everpure reported $3.66B in annual revenue, 70.2% gross margins, and a P/E above 380. The S&P 500 inclusion is expected to drive passive fund buying.

$PMed

Needham raises Everpure stock price target on strong FY28 outlook

Needham raised its price target for Everpure (NYSE:P) to $150 from $140, maintaining a Buy rating. The firm cited Everpure's strong fiscal 2028 outlook, with projected revenue growth of 39% to 45% and operating margins of 24% to 26%. The company also reported second-quarter fiscal 2027 revenue of $1.186 billion, up 38% year-over-year. Several analysts have revised earnings upwards, and the stock has returned 68.3% over the last six months.